Revenue: As of FY2025 Q1, the actual value is USD 48.32 M.EPS: As of FY2025 Q1, the actual value is USD -1.68.EBIT: As of FY2025 Q1, the actual value is USD -81.58 M.<h3>Cell Engineering Segment</h3><ul><li>Revenue: $38.2 million for the three months ended March 31, 2025, compared to $27.9 million for the same period in 2024, an increase of $10.3 million.</li><li>Operating Loss: - $31.6 million for the three months ended March 31, 2025, compared to - $92.3 million for the same period in 2024.</li><li>Research and Development Expenses: $48.7 million for the three months ended March 31, 2025, compared to $81.9 million for the same period in 2024.</li><li>General and Administrative Expenses: $18.0 million for the three months ended March 31, 2025, compared to $38.2 million for the same period in 2024.</li></ul><h3>Biosecurity Segment</h3><ul><li>Revenue: $10.1 million for the three months ended March 31, 2025, compared to $10.1 million for the same period in 2024.</li><li>Operating Loss: - $5.2 million for the three months ended March 31, 2025, compared to - $11.2 million for the same period in 2024.</li><li>Cost of Biosecurity Revenue: $7.2 million for the three months ended March 31, 2025, compared to $9.2 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $51.5 million for the three months ended March 31, 2025, compared to - $89.3 million for the same period in 2024.</li><li>Net Cash Used in Investing Activities: - $198.7 million for the three months ended March 31, 2025, compared to - $12.1 million for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Ginkgo Bioworks Holdings, Inc. plans to continue its R&amp;D activities under existing and new programs, further invest in its Foundry and Codebase, develop and expand its offerings, and maintain, expand, and protect its intellectual property.</li><li>Restructuring Actions: The company is undergoing restructuring actions, including workforce reductions and facility consolidations, which are expected to be substantially completed in 2025.</li></ul>

GINKGO BIOWORKS HOLDINGS INC C/WTS 16/09/2026 (TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 48.32 M